熱門資訊> 正文
Aurinia Pharmaceuticals任命Kevin Tang为首席执行官
2026-03-23 20:22
- Aurinia Pharmaceuticals (AUPH) announced on Monday that Kevin Tang, Aurinia’s Chair of the Board, will succeed Peter Greenleaf as chief executive officer.
- The firm added that Greenleaf will continue as a consultant to facilitate the transition.
- The company has also appointed Ryan Cole as chief operating officer, Michael Hearne as chief financial officer, and Thomas Wei as chief scientific officer.
- Additionally, Stew Kroll and Stephen Robertson will continue in their roles as chief development officer and general counsel, respectively.
- AUPH +0.85% premarket to $14.14.
- Source: Press Release
More on Aurinia Pharma
- Aurinia Pharmaceuticals: Waiting For Another Opportunity (Downgrade)
- Aurinia targets $305M–$315M LUPKYNIS sales for 2026 while advancing aritinercept clinical development
- Seeking Alpha’s Quant Rating on Aurinia Pharma
- Historical earnings data for Aurinia Pharma
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。